Amgen EVP receives 13,403-share stock award

Gordon Murdo reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/05/2026 - 08:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Gordon Murdo reported acquisition or exercise transactions in this Form 4 filing.

Amgen Inc. executive vice president of Global Commercial Operations Murdo Gordon received a grant of 13,403 shares of Amgen common stock as an equity award, with no cash paid per share. After this grant, he directly holds 56,807 shares. The total includes 740 dividend equivalents credited to his unvested restricted stock units, which will be paid in shares on a one-to-one basis according to their vesting schedule.

Insider Trade Summary

Grant/Award: 13,403 shares

Grant/Award 1 txn

Insider Gordon Murdo

Role EVP, Global Commercial Ops

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	13,403	$0.00	$0.00

Holdings After Transaction: Common Stock — 56,807 shares (Direct)

Holdings Before and After: Common Stock, 43,404 to 56,807 shares (Direct)

Footnotes (1)

1. F1. These shares include 740 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Amgen (AMGN) report for Murdo Gordon?

Amgen reported that EVP Global Commercial Operations Murdo Gordon received a grant of 13,403 shares of common stock. This equity award increased his directly held stake to 56,807 shares, reflecting routine stock-based compensation rather than an open-market purchase or sale.

How many Amgen (AMGN) shares does Murdo Gordon hold after this Form 4?

Following the reported grant, Murdo Gordon directly holds 56,807 shares of Amgen common stock. This figure includes shares from the 13,403-share equity award and 740 dividend equivalents attached to his unvested restricted stock units that pay out in stock over time.

Was cash paid for the Amgen (AMGN) shares granted to Murdo Gordon?

No cash was paid for this equity award; the reported transaction price per share was 0.0000. The filing characterizes the 13,403 shares as a grant or award of Amgen common stock, consistent with stock-based compensation under the company’s equity incentive framework.

What are the 740 dividend equivalents mentioned in the Amgen (AMGN) Form 4?

The 740 dividend equivalents are additional rights credited to Murdo Gordon’s unvested restricted stock units under Amgen’s equity incentive plan. They convert into Amgen common shares on a one-to-one basis following the RSUs’ vesting schedule, with cash paid only for any remaining fractional share amounts.

Is Murdo Gordon’s Amgen (AMGN) share ownership direct or through an entity?

The Form 4 states that Murdo Gordon’s ownership is direct, indicated by the code "D" for direct ownership. The filing does not attribute these holdings to any trust, partnership, or other entity, so the reported 56,807 shares are held in his own name.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gordon Murdo

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Global Commercial Ops

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		A		13,403	A	$0	56,807(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares include 740 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

	/s/ Murdo Gordon	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.